Tumour angiogenesis is widely considered to be an important phenomenon in the process of tumour growth and metastasis.
Introduction
Angiogenesis, or tumour neovascularization, is an important phenomenon that occurs when new capillaries necessary for continued tumour growth are formed which then allows for progression and distant metastasis. Many previous studies have suggested that tumour angiogenesis, as measured by intratumoral quanti®cation of microvessel count (MVC), may be a powerful prognostic indicator in many speci®c tumour types, including melanoma, 1, 2 breast cancer, 3±5 carcinoma of the uterine cervix, 6 bladder cancer, 7 non-small cell lung cancer, 8 testicular germ cell tumor, 9 gastric cancer, 10 and prostate cancer. 11±16 In this study, angiogenic activity (quanti®ed MVC) in prostate cancer was investigated using both staining for Factor VIII-related antigen (FVIII-RA) and CD34 Antigen (CD34 Ag) to indicate whether MVC is important as an independent predictor for pathologic stage and progression.
Materials and methods

Patient material
We investigated 101 prostates from patients who underwent radical retropubic prostatectomy for clinically localized adenocarcinoma of the prostate between August, 1983 and October, 1993 at The Methodist Hospital in Houston, Texas. [Eighty cases were selected randomly. We then added 21 cases with seminal vesicle involvement (SVI) (pT3c N0) to ensure adequate representation of advanced prostate cancer for comparison to cancers that were organ-con®ned and those with extraprostatic extension (EPE)]. None of the patients had received preoperative hormonal therapy. The mean age of patients in this study was 63.8 y (range 48±79). Preoperative serum prostate speci®c antigen (PSA) was measured in patients by using immunoenzymatic assay (Hybritech 1 Tandem-R assay) (n 65, range 0.1±100, median 7.3). However, 36 patients were treated before PSA assays were ®rst used in our hospital. The distribution of prostate cancer clinical stage, classi®ed according to the TNM system was: T1a (n 12, T1b (n 19), T1c (n 2), T2a (n 12), T2b (n 33), T2c (n 19), T3 (n 4).
Pathological examination
All the radical prostatectomy specimens were sectioned by whole-mount processing as described previously. 17 The presence or absence of EPE, surgical margins (SM), and SVI was recorded for each prostate by one pathologist (TMW). All cancer foci were graded according to the criteria of Gleason and each Gleason grade was mapped separately on the slides. 18 Of 101 patients, 34 had organcon®ned disease, 29 had EPE only, 31 had SVI, and 7 had pelvic lymph node metastases (( )LN). Twenty-seven patients developed elevated serum PSA postoperatively. Nodal status was determined from the initial surgical pathology report. The total tumour volume (TTV) was measured on the tumour map from the sections by computerized planimetry as described previously. 19 Pathological stage was assigned as follows: pT2 N0 (organcon®ned: n 36), pT3a,b N0 (EPE: n 27), pT3c N0 (SVI: n 31), pT1-3 N1 (lymph node metastasis: n 7).
Vessel staining and counting
To identify microvessels by immunoreactivity with staining endothelial cells, we used both Factor VIII-RA and CD34 Ag on alternately prepared sections. One of the sections was stained with H&E to determine the correct areas of the tumour and to assign a grade according to the Gleason method. 18 
Immunohistochemistry
Immunohistochemistry was performed using an avidin-biotin complex technique. Tissue from each case was processed routinely, ®xed in 10% buffered formalin, and embedded in paraf®n. The archived blocks were sectioned at a thickness of 4 microns and mounted on poly-L-lysine-coated slides. Sections were then deparaf®-nized in Histoclear, rehydrated through graded ethanols, and quenched in 0.3% H 2 O 2 for 30 min.
Staining for von Willebrand Factor (Factor VIII Ag)
Sections were covered with 20% normal goat serum for 30 min. After digestion in pronase (Sigma, St. Louis, MO) for 10 min, polyclonal rabbit antibody to human von Willebrand Factor (Factor VIII) (Dako, Santa Barbara, CA) was applied to the sections at a dilution of 1 : 600 for 90 min at room temperature. After washing in phosphate buffered saline (PBS, pH 7.6) the sections were incubated with biotinylated goat antibodies to rabbit immunoglobulins (Vector Laboratories, Burlingame, CA) for 30 min at room temperature. Slides were washed in PBS buffer and an avidin-biotin-peroxidase complex (ABC Elite, Vector Laboratories) was applied to the sections following the manufacturer's speci®cations. The slides were then developed using diaminobenzidine (Sigma, St. Louis, MO) with H 2 O 2 to produce a brown color reaction product and were counterstained with methyl green.
Staining for CD34 antibody
Sections were covered with 20% normal horse serum for 20 min. Mouse monoclonal antibody to human CD34 Antigen (QBENDa10, BIio Genex, San Ramon, CA) was applied to the sections at a dilution of 1 : 100 for 60 min at room temperature. Slides were rinsed in PBS buffer and incubated with biotinylated horse antibodies to mouse immunoglobulins (Vector Laboratories, Burlingame, CA) for 30 min at room temperature. Slides were washed in PBS buffer and an avidin-biotin-peroxidase complex (ABC Elite, Vector Laboratories) was applied to the sections following the manufacturer's speci®cations. The slides were then developed using diaminobenzidine (Sigma, St. Louis, MO) with H 2 O 2 to produce a brown color reaction product and were counterstained with methyl green.
Vessel counting
Microvessels were counted using the modi®ed method reported by Weidner and associates. 3±5, 11 After the`hot' (high vascularity) areas were identi®ed by scanning with light microscopy at low power (X40 and X100), the areas of microvessels of each Gleason grade were counted on X200 ®elds (X20 objective and X10 ocular, 0.785 mm 2 ). Any dark brown-staining endothelial cell or cell cluster, clearly separated from adjacent microvessels, tumour cells, or other stromal cells, was considered as a single vessel. In most of the 101 patients, ®ve`hot' ®elds of each Gleason grade were counted. (For 21 cases with smaller cancer foci, less than 5 ®elds were counted. In 8 cases, 4 ®elds; in 11 cases, 3 ®elds; and in 2 cases, 2 ®elds.) Determination of MVC was done by one investigator (A.A.) without knowledge of clinical information. Results are described as the highest number of microvessels within ®ve X200 ®elds in the primary and the worst Gleason grade. Eight cases for FVIII staining, and one case for CD34 staining were not counted because high background staining interfered with the analysis.
DNA ploidy analysis
DNA ploidy was determined with the CAS 200 image analysis system (Becton-Dickenson, San Jose, CA) using paraf®n sections from the prostatectomy specimen. Tumours were classi®ed as diploid or non-diploid (a tetraploid or an aneuploid tumour was classi®ed as non-diploid') as previously described. 20 Twenty-three of the specimens were diploid and 64 were non-diploid. In 14 of the cases, the paraf®n blocks were exhausted of tumour so that DNA ploidy could not be determined by this method.
Patient follow-up
Patients were followed postoperatively with a regularly scheduled history and physical examination, including digital rectal examination (DRE) and measurement of serum PSA every three months for 1 y, every six months until the ®fth year, and then annually. The duration of follow-up ranged from 2±139 months (mean 82 months), with 93% of patients having follow-up of at least 2 y. Progression of disease was de®ned as a consistent elevation of PSA above a level of 0.4 ngamL.
The statistical analyses were performed using the STATA 1 (College Station, TX) software package.
Results
Sixty-®ve patients (64%) had cancer that was not con®ned and 36 patients (36%) had con®ned cancer (Table  1) . Of these 65 patients, 38 (58%) had SVI andaor ( )LN and 27 (42%) had EPE only. When patients with con®ned cancer were compared to those with noncon®ned cancer (pT3a±c N0±1), there were highly signi®cant differences with regard to preoperative PSA (P 0.0001), TTV (P 0.0001), Gleason score (P`0.0005), and MVC (P 0.0001). However, when patients with SVI andaor ( )LN (pT3c N0±1, n 38) were omitted from the analysis, the differences in each group with respect to PSA, TTV, Gleason score, and MVC were not as highly signi®cant [PSA (P`0.005), TTV (P`0.05), primary Gleason grade (P`0.05), and MVC for FVIII-RA (P`0.05)]. When patients without SVI and with negative nodes (pT1±2, 3ab N0, n 63) were compared to those with SVI andaor LN (pT3c N0±1, n 31), there were signi®cant differences with respect to preoperative PSA (P`0.001), TTV (P 0.01), Gleason score (P`0.005) and MVC for FVIII and CD34 Ag staining on both primary and worst grades. (P`0.0005). Seven patients (7%) had lymph node metastasis. Of these patients 4 had pT3c N1 cancer and the remaining 3 had pT3a,b N1 cancer. There was a signi®cant difference in MVC for CD34 Ag staining between patients with ( )LN and negative LN (P`0.01). 
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There were signi®cant differences with respect to PSA (P 0.0001), TTV (P`0.0001), Gleason score (P`0.005), and MVC for FVIII±RA and CD34 Ag staining in each pathologic stage (all P`0.0001). MVC (FVIII±RA, CD34 Ag) signi®cantly increased with increasing pathological stage (Table 1) . Also, both types of MVC staining showed MVC increase as the Gleason grade increased. (FVIII±RA: P 0.0001, CD34 Ag: P`0.0001) ( Table 2) .
DNA ploidy
For DNA ploidy, 23 (26%) patients had diploid tumours and 64 (74%) patients had non-diploid tumours (tetraploid or aneuploid tumours). Nondiploid tumours had a signi®cantly higher MVC on CD34 Ag staining than diploid tumours (P 0.0023) ( Table 2 ). There was no signi®cant difference in MVC on FVIII staining between non-diploid tumours and diploid tumours. (Table 2 ).
Progression
Of the 101 patients in this study, 28 (28%) have disease progression (PSA recurrence) and 73 (72%) do not (Table  3) . A comparison of patients with and without progression showed signi®cant differences with MVC for FVIII± RA and CD34 Ag staining on the worst Gleason grade (FVIII±RA: P`0.005, CD34 Ag: P`0.001). Kaplan±Meier plots for each staining method are shown in Figures 1a and 1b. We selected MVC`cut-offs' at 120 for FVIII±RA and 160 for CD34 staining. There were signi®cant differences between the two groups (Logrank test: P 0.001 for FVIII, P 0.0001 for CD34 Ag).
Correlation analysis and multivariate analysis of Gleason score, MVC, PSA, DNA ploidy and TTV MVC correlated with various prognostic factors. MVC using FVIII staining correlated with pathologic stage, Gleason score, and preoperative PSA (P`0.001). In addition, MVC using CD34 Ag staining also correlated with TTV and DNA ploidy. There was a signi®cant difference in MVC between the group of patients with greater than 4.0 ngaml and the group with less than 4.0 ngaml preoperative PSA levels (FVIII±RA: P`0.05, CD34 Ag: P`0.0005). Tumours larger than 3.1 cm 3 tended to have higher MVC than tumours less than 3.1 cm 3 with both staining methods (FVIII±RA: P`0.05, CD34 Ag: P`0.01).
To determine if any of the variables (MVC, Gleason score, TTV and DNA ploidy) might be strongly associated with interval to progression after radical prostatectomy, we used the Cox proportional hazards models analysis. The results are given in Table 4 . Although the pathologic stage, Gleason score and MVC (FVIII and CD34) had signi®cant univariate effects, in multivariate analysis neither MVC (FVIII and CD34), TTV, nor DNA ploidy proved to be independent prognostic indicators beyond information provided by the pathologic stage or Gleason score. In this multivariate analysis, the Gleason score was the most powerful, independent predictor of progression (P 0.001). 
Discussion
Prostate cancer is the most common cancer of men in United States and the second leading cause of cancer death in men, second only to cancer of the lung. 21 Many studies have examined various prognostic indicators. We analyzed several clinical and pathological variables (age, preoperative PSA, Gleason grade in the radical prostatectomy specimens, TTV, DNA ploidy, and MVC) to determine which factors would provide useful prognostic information for prostate cancer. Recently tumour angiogenesis has emerged as an important factor in growth and progression of solid neoplasms. Folkman et al 22±26 suggested that tumour cells, tumour-associated in¯ammatory cells (macrophages, mast cells), and extracellular matrix export angiogenic molecules. Then angiogenic molecules stimulate endothelial-cell proliferation and increased capillary supply for continued tumour growth. Tumour metastasis is also angiogenesis-dependent; new capillaries supply a doorway for entry of metastases to the circulatory system.
22±26
Many studies (tumour neovascularization) for breast cancer, 3À5 cutaneous melanoma, 1±2 uterine cervix, 6 neoplastic lesions of the bladder, 7 non-small cell lung cancer, 8 testicular germ cell tumour, 9 and gastric cancer 10 have shown that tumour angiogenesis is one of the most important prognostic predictors. A recent report indicated that MVC in needle biopsies correlated with EPE in the prostatectomy specimen. Use of MVC added signi®-cant prognostic information when combined with preoperative PSA and Gleason sum. 27 In the other studies of tumour neovascularization, MVC was greater in prostatic intraepithelial neoplasia (PIN) and prostate cancer compared with hyperplastic lesions and normal prostatic epithelium. 14, 28 Also MVC has been shown to be a predictor of metastasis of prostate cancer to lymph nodes 11, 16 and bone marrow. 15 One recent study reported that the center of the neoplasm had higher angiogenic activity than adjacent benign tissue or the periphery of the tumour. 29 It has been suggested that other endothelial markers such as CD31 and CD34 are more sensitive than FVIII to identify microvessels. 30 CD31 has complete speci®city for endothelium. When CD31 is compared to CD34, it is clear that CD34 has a much broader and less speci®c reactivity. CD34 should not be used by itself to con®rm an endothelial tumour because it is also an important marker for the spindle cells of Kaposi sarcoma, solitary ®brous tumours, and dermato®brosarcoma. 30±35 Thus, CD34 has a much broader reactivity but still has a speci®city for endothelial cells in the appropriate setting. In our series, CD34 crossreacted with occasional ®broblasts, tumour cells, lymphocytes, and plasma cells. In areas where this cross-reaction occurred, other countable areas were found. In our series, we found that the number of microvessels was consistently higher with CD34 Ag staining than with FVIII±RA staining, suggesting that the former method is more sensitive than the latter.
Epstein et al 36 studied the effects of positive surgical margins, Gleason score, and capsular penetration on disease progression. In their study, all three of these factors were independent predictors of progression. In our MVC series, when patients with SVI andaor ( )LN were included, we found signi®cant differences between patients with EPE and without EPE. In contrast, when patients with SVI andaor ( )LN metastasis were excluded, there was no difference in MVC (by CD34 staining) between patients with EPE and those without EPE. However, there was weak difference with FVIII±RA staining. These differences are explained by the fact that 79% of patients with SVI andaor ( )LN had EPE; MVD for these cases was signi®cantly higher than for patients without SVI andaor ( )LN. The difference in MVC between patients with SVI and without SVI was highly signi®cant. Also, there were highly signi®cant differences between the two groups of patients classi®ed as advanced (namely patients with SVI andaor ( )LN) or not advanced. The number of patients who had evidence of SVI in the radical prostatectomy specimens was 31. Except for patients with lymph node metastases, these patients have the worst prognosis. According to recent studies, SVI correlates with TTV and Gleason grade.
37±39
Our study suggests that the occurrence of SVI may be related to tumour neovascularization; however, the precise mechanism of the relationship of tumour angiogenesis to SVI is uncertain.
Conclusions
We sought to determine which variables were independent prognostic predictors in radical prostatectomy specimens in a group with (1) quantitative MVC of both immunohistochemical staining FVIII±RA and CD34 Ag on each Gleason grade (2) long-term follow-up and (3) with use of preoperative PSA, TTV, and DNA ploidy as prognostic predictors. In our series, the Cox proportional hazards model indicated that the Gleason score was the strongest independent prognostic indicator. Our study demonstrates that many traditional prognostic indicators in prostate cancer (preoperative PSA, TTV, DNA ploidy, Gleason grade, and MVC) are highly interrelated. As Brawer et al 12 points out, in the future MVC may provide useful information if it is applied to biopsy material. The comparison of MVC heterogeneity in biopsy material vs prostatectomy specimens, however, requires further investigation. Additional studies on tumour angiogenesis, particularly on biopsy material, may be necessary to assess the role of MVC in the prognosis and treatment of prostate cancer.
